Lung Cancer Clinical Trials in Chicago

Showing 781-784 of 784 trials

Inhaled Doxorubicin Plus IV Docetaxel and Cisplatin in Patients With Non-Small-Cell Lung Carcinoma (NSCLC)

NCT00082472

This study is intended to show whether inhaled chemotherapy can be added to a standard IV chemotherapy regime, to investigate the additional toxicities and to show initial evidence of efficacy of the combination.

NSCLC

Zivena30 participantsStarted Jan 2004

New Haven, Connecticut, United States • Las Vegas, Nevada, United States • Las Vegas, Nevada, United States +3 more locations

TERMINATEDPhase 1202 miles

Phase I Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile Of Lenalidomide (Revlimid®, CC-5013) With Pemetrexed In Subjects With Advanced Non-Small Cell Lung Cancer

NCT00179699

Study will deteremine the MTD and evaluate the safety profile of oral lenalidomide on days 1-14 when combined with pemetrexed on day 1 of a 21 days cycle. Subjects will continue on study until documention of disease progression.

Non-Small Cell Lung Cancer

Celgene Corporation40 participantsStarted Sep 2005

Orlando, Florida, United States • Iowa City, Iowa, United States • Louisville, Kentucky, United States +2 more locations

UNKNOWNPhase 2409 miles

Study of DN-101 (Calcitriol) and Docetaxel in Subjects Previously Enrolled in Studies DN101-002 or DN101-004

NCT00285675

The purpose of this study is to monitor the safety of continued DN-101 and docetaxel treatment for subjects previously enrolled in DN101-002 (ASCENT) or DN101-004 (NSCLC) Studies.

Androgen Independent Prostate Cancer (AIPC)Non Small Cell Lung Cancer (NSCLC)

Novacea25 participantsStarted Apr 2006

Berkeley, California, United States • San Francisco, California, United States • Vallejo, California, United States +10 more locations

Inhaled Doxorubicin Plus IV Docetaxel and Cisplatin in Patients With Non-Small-Cell Lung Carcinoma (NSCLC)

Phase I Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile Of Lenalidomide (Revlimid®, CC-5013) With Pemetrexed In Subjects With Advanced Non-Small Cell Lung Cancer

Study of DN-101 (Calcitriol) and Docetaxel in Subjects Previously Enrolled in Studies DN101-002 or DN101-004

Lung Cancer Trials in Other Cities

Safety and Immunogenicity of Recombinant DNA and Adenovirus Expressing L523S Protein in Early Stage Non-Small Cell Lung Cancer

Other Conditions in Chicago